Basic Information
Latvia's Latima company is a firm focused on the research and development of oncolytic virus drugs. The ECHO-7 type oncolytic virus developed by this company has over 60 years of research history. Rigvir, a genetically modified ECHO-7 enterovirus developed by Latvia's Latima company, is the world’s first marketed oncolytic virus.